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Starvation blocks the actions of growth hormone
(GH) and inhibits growth through mechanisms that
are not well understood. In this report, we demon-
strate that fibroblast growth factor 21 (FGF21), a hor-
mone induced by fasting, causes GH resistance. In
liver, FGF21 reduces concentrations of the active
form of signal transducer and activator of transcrip-
tion 5 (STAT5), a major mediator of GH actions, and
causes corresponding decreases in the expression
of its target genes, including insulin-like growth fac-
tor 1 (IGF-1). FGF21 also induces hepatic expression
of IGF-1 binding protein 1 and suppressor of cytokine
signaling 2, which blunt GH signaling. Chronic expo-
sure to FGF21 markedly inhibits growth in mice.
These data suggest a central role for FGF21 in inhib-
iting growth as part of its broader role in inducing the
adaptive response to starvation.
INTRODUCTION
Growth hormone (GH) is synthesized and secreted by somato-
trophs in the anterior pituitary to regulate diverse physiological
processes including growth and metabolism (Herrington et al.,
2000; LeRoith and Yakar, 2007). Many of the anabolic actions
of GH are mediated by insulin-like growth factor 1 (IGF-1). GH in-
duces IGF-1 transcription through a complex, regulatory cas-
cade that is initiated when GH binds to the GH receptor (GHR)
on the cell surface. This interaction causes the GHR to activate
janus kinase 2 (JAK2), which in turn phosphorylates members
of the signal transducers and activators of transcription (STAT)
family. Once phosphorylated, STAT proteins translocate to the
nucleus, where they bind to response elements in the regulatory
regions of target genes including IGF-1. STAT5A and STAT5B
have prominent roles in mediating the downstream effects of
GH (Herrington et al., 2000). Mice lacking both STAT5A and
STAT5B are 20%–40% smaller than their wild-type littermates
and are resistant to the anabolic actions of exogenous GH
(Teglund et al., 1998).
Starvation and malnutrition lower circulating levels of IGF-1
(Thissen et al., 1994). This reduction is caused in part by a de-crease in IGF-1 mRNA levels in liver, where most IGF-1 is
made (Bornfeldt et al., 1989; Emler and Schalch, 1987; Lowe
et al., 1989; Maes et al., 1983). Fasting also decreases hepatic
mRNA levels and circulating concentrations of acid-labile sub-
unit (ALS), which complexes with IGF-1 to stabilize it (Kong
et al., 2002). While the mechanism underlying these fasting-in-
duced effects is not known, a recent study showed that fasted
rats have reduced hepatic phosphorylation of STAT5 in response
to injected GH, suggesting that fasting might inhibit transcription
of the IGF-1 and ALS genes by reducing STAT5 activity (Beau-
loye et al., 2002).
Fibroblast growth factor 21 (FGF21) is an atypical member of
the FGF family that functions as an endocrine hormone (Kharito-
nenkov et al., 2005). In mice, FGF21 is induced in liver by fasting
through a mechanism that requires the nuclear fatty acid recep-
tor, peroxisome proliferator-activated receptor a (PPARa) (Bad-
man et al., 2007; Inagaki et al., 2007; Lunda˚sen et al., 2007).
FGF21 induces the synthesis of ketone bodies, which are the
principal source of energy during prolonged fasting and starva-
tion. FGF21 also sensitizes mice to the energy-conserving state
of torpor, which is characterized by decreased body tempera-
ture and physical activity (Inagaki et al., 2007). In this report,
we show that FGF21 inhibits STAT5 signaling and blunts growth,
revealing a broader role for FGF21 in promoting energy conser-
vation during starvation.
RESULTS
FGF21-Transgenic Mice Have Reduced Growth
We previously generated transgenic mice that express FGF21
under the control of the apolipoprotein E promoter (Inagaki
et al., 2007). Plasma FGF21 concentrations in these transgenic
mice are 5-fold higher than those in fasted wild-type mice
(Figure 1A). Notably, both male and female FGF21-transgenic
mice were markedly smaller than their wild-type counterparts
(Figure 1B). Although wild-type and FGF21-transgenic mice
weighed the same at birth (data not shown), FGF21-transgenic
mice gained less weight than wild-type mice (Figure 1C). There
was a significant reduction in tibia length in both male and female
FGF21-transgenic mice (Figure 1D). Food consumption normal-
ized to body weight was significantly increased in male FGF21-
transgenic mice and trended higher in female FGF21-transgenic
mice, and body composition studies showed increased adipos-
ity in both male and female FGF21-transgenic mice (Figure S1).Cell Metabolism 8, 77–83, July 2008 ª2008 Elsevier Inc. 77
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growth without causing hypophagia.
FGF21 Reduces Serum IGF-1
Plasma GH and IGF-1 concentrations were measured in wild-
type and FGF21-transgenic mice. Interestingly, GH concentra-
tions were significantly increased in FGF21-transgenic mice
(Figure 2A). Despite this increase in circulating GH, there was
a >50% decrease in serum IGF-1 concentrations (Figure 2A).
Thus, FGF21-transgenic mice are GH resistant.
Approximately 75% of circulating IGF-1 is synthesized in the
liver (Yakar et al., 1999). IGF-1 mRNA levels were reduced by
30% in livers of FGF21-transgenic mice but were not changed
in other tissues, including skeletal muscle, kidney, and ovary
(Figure 2B; data not shown). FGF21-transgenic mice also had
an 40% decrease in hepatic ALS mRNA (Figure 2B). Analysis
of IGF-1 binding protein expression revealed a dramatic increase
in hepatic IGFBP-1mRNA (Figure 2B), which is induced by fasting
(Murphy et al., 1991). IGFBP-1-transgenic mice have both intra-
uterine and postnatal growth retardation, suggesting that
IGFBP-1 is involved in sequestering IGF-1 during periods of nutri-
tional deprivation (Baxter and Martin, 1989; Silha and Murphy,
2002; Underwood et al., 1994). The coordinate changes in hepatic
IGF-1, ALS, and IGFBP-1 expression likely account for the
marked decrease in circulating IGF-1 in FGF21-transgenic mice.
FGF21 Inhibits STAT5
Since both IGF-1 andALS are induced and IGFBP-1 is repressed
by STAT5 in liver (Davey et al., 2001; Ono et al., 2007; Senevir-
atne et al., 1990; Woelfle and Rotwein, 2004), we examined
whether other STAT5-regulated genes are changed in the
FGF21-transgenic mice. Significant decreases were seen in
Figure 1. FGF21 Inhibits Growth
(A) Plasma FGF21 concentrations were measured in wild-
type (WT) and FGF21-transgenic (Tg) mice in either the fed
state or after a 24 hr fast. n = 5 male mice/group. **, p <
0.01 compared to WT, fed group.
(B) Male and female WT and Tg mice are shown.
(C) Body weights are shown for male (squares) and female
(circles); WT (open symbols) and Tg mice (closed sym-
bols). n = 5 mice/group. *, p < 0.05; **, p < 0.01; ***, p <
0.001 compared to WT mice of same sex.
(D) Tibia length was measured in male and female WT and
Tg mice. n = 4 mice/group. **, p < 0.01. In this and all other
figures, error bars represent the mean ± SEM.
FGF21-transgenic mice in the hepatic mRNA
levels of major urinary proteins (MUP) 1 and 3,
CYP2D9, solute carrier organic anion trans-
porter family member 1a1 (SLCO1A1), and hy-
droxysteroid dehydrogenase 3b5 (HSD3B5)
(Figure 2B). By contrast, sulfotransferase family
1Emember 1 (SULT1E1)mRNA levels were dra-
matically increased in FGF21-transgenic mice
(Figure 2B). These changes in gene expression
mirror those seen in STAT5A/B-knockout mice
(Holloway et al., 2007). To determine directly
whether STAT5 is altered in FGF21-transgenic
mice, total and phosphorylated STAT5 levels were measured in
whole-cell and nuclear extracts prepared from livers of wild-
type and FGF21-transgenic mice. Although there was no change
in total STAT5 protein levels, there was a striking decrease in
phosphorylated STAT5 levels and corresponding decreases in
the concentrations of nuclear STAT5A and STAT5B in FGF21-
transgenic mice (Figure 3A). Thus, both the STAT5A and STAT5B
isoforms are affected. Injection of pharmacologic concentrations
of recombinant GH into FGF21-transgenic mice acutely restored
STAT5 phosphorylation (Figure S2). Taken together, these data
demonstrate that STAT5 activity is strongly impaired in FGF21-
transgenic mice. We note that IGFBP-1 and other fasting-in-
duced genes are regulated by the transcription factor FOXO1
(Guo et al., 1999). However, nuclear FOXO1 protein levels were
unchanged in livers of FGF21-transgenic mice (Figure S3),
suggesting that FGF21 does not affect FOXO1 signaling.
JAK2 plays an important role in the phosphorylation and acti-
vation of STAT5 (Herrington et al., 2000). While there was little or
no change in total JAK2 protein levels in livers of FGF21-trans-
genic mice, phosphorylated JAK2 concentrations were in-
creased in the FGF21-transgenic mice (Figure 3A). These data
indicate that FGF21 interrupts the GH-signaling cascade down-
stream of JAK2.
Suppressor of cytokine signaling 2 (SOCS2) inhibits the GH-
signaling cascade (Leroith and Nissley, 2005; Rico-Bautista
et al., 2006). In livers of FGF21-transgenic mice, there was a sig-
nificant increase in SOCS2 mRNA (Figure 3B) but no changes in
the mRNAs encoding the SOCS2-related proteins cytokine-in-
duced Src homology 2 protein and SOCS3 (data not shown).
Western analysis revealed a corresponding increase in SOCS2
protein in livers of FGF21-transgenic mice (Figure 3B). These
data suggest that increased SOCS2 activity may contribute to78 Cell Metabolism 8, 77–83, July 2008 ª2008 Elsevier Inc.
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mice.
Shorter-Term Exposure to FGF21 Inhibits STAT5
Activity
Two strategies were used to test whether shorter-term exposure
to FGF21 also inhibits STAT5 activity. Since FGF21 can be in-
duced efficiently by PPARa, we first examined whether adminis-
tration of the PPARa agonist, Wy14643, affects the GH-STAT5
pathway. Because Wy14643 causes a decrease in food con-
sumption, pair-fed studies were performed. Wy14643 adminis-
tration for 10 days caused a 5-fold increase in hepatic FGF21
mRNA (Figure S4A) and decreased concentrations of phosphor-
ylated STAT5 (Figure 4). Corresponding decreases occurred in
hepatic IGF-1 and ALS mRNAs levels and serum IGF-1 concen-
trations. Wy14643 treatment also caused significant increases in
hepatic IGFBP-1 mRNA and SOCS2 protein levels (Figure 4).
Thus, administration of a PPARa agonist recapitulates the
effects of long-term FGF21 exposure on the GH-STAT5 axis.
While the Wy14643 experiments were consistent with the hy-
pothesis that induction of FGF21 interferes with the GH-STAT5
signaling pathway, they were not definitive. To determine directly
whether short-term exposure to FGF21 blunts the GH-STAT5
Figure 2. FGF21 Causes GH Resistance
(A) GH and IGF-1 concentrations in plasma from wild-type (WT) and
FGF21-transgenic (Tg) mice. n = 8 male mice/WT group, 11 male
mice/Tg group.
(B) mRNA levels of the indicated genes were measured by RT-qPCR in
livers from WT and Tg mice. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Error
bars represent the mean ± SEM.
axis, mice were injected with recombinant FGF21 for either
1 or 3 days. Notably, significant decreases in hepatic levels
of phosphorylated STAT5 and circulating IGF-1 concen-
trations occurred as early as 1 day postinjection (Figure 4).
The decrease in plasma IGF-1 concentrations was accom-
panied by increased IGFBP-1 mRNA levels and modest
decreases in IGF-1 and ALS mRNA levels (Figure 4).
Short-term FGF21 administration also increased SOCS2
protein concentrations (Figure 4). Importantly, the changes
in hepatic levels of phosphorylated STAT5 and SOCS2
protein, IGFBP-1 mRNA, and plasma IGF-1 caused by
short-term FGF21 administration were comparable
in magnitude to those caused by a 24 hr fast (Figure 4),
which induced hepatic FGF21 mRNA levels 10-fold
(Figure S4B). FGF21 administration also caused a de-
crease in plasma insulin concentration that was similar in
magnitude to that caused by fasting (Figure 4). Interest-
ingly, this decrease in insulin was not seen in mice admin-
istered Wy14643, revealing differences in the actions of
Wy14643 and FGF21. Overall, these data provide strong
evidence that FGF21 plays an important role in downregu-
lating the GH-STAT5 signaling pathway during fasting.
DISCUSSION
Although it is well established that fasting blunts GH
actions and reduces circulating IGF-1 concentrations in
a variety of different mammalian species, including man (Thissen
et al., 1994), the molecular underpinnings of this phenomenon
have remained obscure. In this report, we show that the fast-
ing-induced hormone, FGF21, elicits the same spectrum of ef-
fects as fasting on the GH-signaling cascade, including elevated
plasma GH concentrations and decreased circulating IGF-1
levels. Moreover, chronic exposure of mice to FGF21 strongly in-
hibits growth. Taken together, these findings suggest that FGF21
plays a central role in causing growth-hormone resistance in re-
sponse to nutrient deprivation. Since GH exerts powerful effects
on carbohydrate and lipid metabolism (Clemmons, 2004; David-
son, 1987; LeRoith and Yakar, 2007), these findings also raise
the possibility that inhibition of the GH axis contributes to the
diverse metabolic actions of FGF21.
FGF21 caused a marked reduction in hepatic concentrations of
phosphorylated STAT5 and corresponding decreases in STAT5-
regulated genes, including IGF-1 and ALS. These changes along
with the upregulation of IGFBP-1, which is repressed by GH
through a STAT5B-dependent mechanism (Ono et al., 2007; Sen-
eviratne et al., 1990), are likely to account for the changes that are
seen in IGF-1 levels in FGF21-transgenic mice. Notably, the
FGF21-transgenic mice closely resemble STAT5A/B-knockout
mice in several key respects. First, FGF21-transgenic mice andCell Metabolism 8, 77–83, July 2008 ª2008 Elsevier Inc. 79
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gene expression, including reduced IGF-1, ALS, MUP1, MUP3,
SLCO1A1, and HSD3B5 mRNAs and increased SULT1E1
mRNA (Holloway et al., 2007). Second, the 50% decreases in
serum IGF-1 concentrations and body weight in FGF21-trans-
genic mice are comparable to the changes reported for
STAT5A/B-knockout mice (Teglund et al., 1998). Finally, female
FGF21-transgenic mice are infertile and have few or no corpora
lutea as reported for the STAT5A/B-knockout mice (V.Y.L.,
D.J.M., and S.A.K, unpublished data) (Teglund et al., 1998). Taken
together, the striking similarities between the FGF21-transgenic
and STAT5A/B-knockout mice strongly suggest that many of
the effects of FGF21 are mediated through inhibition of STAT5.
How does FGF21 reduce phosphorylated STAT5 levels? We
show that FGF21 inhibits the GH-signaling pathway downstream
of JAK2. FGF21 increased hepatic levels of SOCS2, which func-
tions as a potent negative regulator of GH signaling in vivo (Leroith
and Nissley, 2005; Rico-Bautista et al., 2006). SOCS2-knockout
mice are significantly larger than wild-type mice, and this in-
creased growth requires both GH and STAT5B (Greenhalgh
et al., 2002, 2005; Metcalf et al., 2000). Since SOCS2 binds to
the tyrosine-phosphorylated GHR, it might blunt GH signaling by
competing with STAT5 for access to the GHR. The induction of
SOCS2 by FGF21 is surprising in that SOCS2 is also induced by
GH and STAT5B (Davey et al., 1999; Woelfle and Rotwein,
2004), presumably as part of a feedback loop that attenuates GH
signaling.Our results suggest that there is anadditional, STAT5-in-
dependent mechanism through which SOCS2 can be induced by
Figure 3. FGF21 Reduces STAT5 Phosphorylation
(A) Phosphorylated STAT5 (P-STAT5), total STAT5, STAT5A, STAT5B,
phosphorylated JAK2 (P-JAK2), and total JAK2 protein levels were mea-
sured by immunoblotting in hepatic whole-cell extracts (WCE) or nuclear
extracts (NE) from wild-type (WT) or FGF21-transgenic (Tg) mice. b-actin
and lamin B were used as loading controls. Immunoblotting was done with
equal amounts of protein pooled from four male mice. Quantification by
densitometry is indicted below each band.
(B) SOCS2 mRNA and protein levels were measured by RT-qPCR and im-
munoblotting, respectively, in livers from WT and Tg mice. n = 7 male
mice/group. **, p < 0.01. Error bars represent the mean ± SEM.
FGF21. We note that we have been unable to recapitulate the
effects of FGF21 on STAT5 activity or SOCS2 expression inpri-
mary cultures of mouse or rat hepatocytes treated with FGF21
for periods of 1–3 days. One explanation for these data is that
FGF21 does not act directly on the liver but instead through an
indirect mechanism. In this regard, FGF21 does not efficiently
activate FGF receptor 4, the predominant FGF receptor in liver
(Ogawa et al., 2007; Suzuki et al., 2008). An alternate explana-
tion is that primary hepatocytes have lost their ability to
respond to FGF21 during the culturing process.
While FGF21 causes many of the same effects as fasting on
the GH axis, there were two notable differences. First,
whereas fasting in rats caused resistance to GH-mediated
phosphorylation of JAK2 (Beauloye et al., 2002), hepatic levels
of phosphorylated JAK2 were increased in FGF21-transgenic
mice. Second, whereasSOCS3mRNA is increased in livers of
fasting rats (Beauloye et al., 2002), we did not detect any
changes in hepaticSOCS3mRNA levels in FGF21-transgenic
mice (data not shown). These differences may be a consequence
of either species-specific differences or the contributions of other
signaling pathways to the fasting response.
Transcription of the FGF21 gene is stimulated directly by
PPARa (Badman et al., 2007; Inagaki et al., 2007; Lunda˚sen
et al., 2007). As predicted, treatment of mice with a synthetic
PPARa agonist elicited the same spectrum of effects as FGF21
on the GH/IGF-1 pathway, including reduced hepatic levels of
phosphorylated STAT5, decreased IGF-1 and ALS mRNA levels,
and increased SOCS2 concentrations. Crosstalk between
PPARa and STAT5B has been previously described in cell-
based assays, with GH-activated STAT5B-inhibiting PPARa-
regulated gene transcription, and conversely, ligand-activated
PPARa-inhibiting STAT5B-regulated transcription (Shipley and
Waxman, 2004). Thus, crosstalk between PPARa and STAT5
may occur at multiple levels. Notably, in clinical studies, the
PPARa-agonist bezafibrate significantly lowers IGF-1 levels in
patients (Ruotolo et al., 2000). This finding together with data
showing that FGF21 expression is induced by PPARa agonists
in primary human hepatocytes (Inagaki et al., 2007; Lunda˚sen
et al., 2007) suggest that the PPARa/FGF21 pathway may be
operative and affect IGF-1 signaling in humans.
EXPERIMENTAL PROCEDURES
Animal Experiments
All animal experiments were approved by the Institutional Animal Care and Re-
search Advisory Committee at the University of Texas Southwestern Medical80 Cell Metabolism 8, 77–83, July 2008 ª2008 Elsevier Inc.
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light/dark cycles and fed standard rodent chow ad libitum. For fasting-refeed-
ing experiments, the nonfasted group was fed ad libitum and the fasted
group was fasted for 24 hr and killed at the end of the dark cycle. For the
Figure 4. FGF21, PPARaActivation, and FastingHave Similar Effects
on the IGF-1 Pathway
Mice were administered vehicle (Veh) or Wy14643 (Wy) for 10 days (left
panels), Veh or FGF21 for 1 or 3 days (middle panels), or were fed or fasted
for 24 hr (right panels). Plasma IGF-1 concentrations, hepatic IGF-1, ALS,
and IGFBP-1 mRNA levels, hepatic phosphorylated STAT5 (P-STAT5), and
SOCS2 protein levels and plasma insulin levels were measured. n = 4–6
mice/group except for 1 day FGF21 treatment group, where n = 3. Male
mice were used in the FGF21, fasting experiments, and female mice in the
Wy14643 experiment. *, p < 0.05; **, p < 0.01; ***, p < 0.001. For the middle
panels, the presence of different lowercase letters indicates statistical signifi-
cance (p < 0.05) between groups. Error bars represent the mean ± SEM.FGF21-administration experiments, mice were injected subcutaneously with
recombinant FGF21 protein (0.75 mg/kg) or vehicle. Mice were injected at
the beginning of the dark cycle and 2 hr prior to sacrifice at 10 a.m. The 1-
day-treatment group was injected with vehicle for 2 days prior to FGF21 ad-
ministration so that all mice underwent the same number of injections during
the 3 day period. For experiments with Wy14643 (Chemsyn Science Laborato-
ries, Harrisonville, MO), mice were treated daily with Wy14643 (50 mg/kg/day
in 1% Tween-80, 1% methylcellulose) or vehicle by gavage for 10 days. Since
PPARa agonists can cause hypophagia, pair-fed studies were performed by
restricting food intake in vehicle-treated mice to the amount ingested by
Wy14643-treated animals given unlimited access to food. To measure tibia
length, isolated tibia were incubated in protein lysis buffer containing 50 mM
Tris, 100 mM EDTA, 100 mM NaCl, 1% SDS, and 0.2 mg/ml proteinase K at
55C overnight and the length measured using digital calipers (Marathon
Watch Company, Ltd., Richmond Hill, ON, Canada).
Plasma Measurements
Plasma FGF21 concentrations were measured using a radioimmunoassay kit
(Phoenix Pharmaceuticals, Inc., Belmont, CA). Plasma IGF-1 and GH concen-
trations were measured using ELISA kits (Diagnostic Systems Laboratories,
Inc., Webster, TX). Plasma insulin was measured using an ELISA Kit (Crystal
Chem Inc., Downers Grove, IL).
Immunoblot Analyses
To prepare whole-cell extracts, 100 mg of liver were homogenized in 1 ml
buffer (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 30 mM sodium phosphate,
50 mM sodium fluoride, 1 mM sodium vanadate, 10% glycerol, and 0.5%
NP40 [pH at 7.4], containing Complete Protease Inhibitor Cocktail [Roche Di-
agnostics, Indianapolis, IN]). After centrifugation at 16,000 g for 5 min at 4C,
the supernatant was collected. To prepare nuclear extracts, 100 mg of liver
were homogenized in 1.2 ml buffer (20 mM Tris-HCl, 2 mM MgCl2, 0.25 M su-
crose, 10 mM EDTA, 10 mM EGTA, 5 mM DTT, 50 mM sodium fluoride, and 1
mM sodium vanadate [pH at 7.4], containing Complete Protease Inhibitor
Cocktail). After centrifugation at 1500 g for 5 min at 4C, the pellet was resus-
pended in 1.8 ml of the same buffer and centrifuged at 1500 g for 8 min at 4C.
The pellet was resuspended in 0.3 ml of extraction buffer (20 mM HEPES, 2.5%
glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 50 mM
sodium fluoride, and 1 mM sodium vanadate containing Complete Protease
Inhibitor Cocktail), rotated at 4C for 45 min and centrifuged at 355,000 g for
20 min. The supernatant was collected. Immunoblotting was performed using
a phospho-STAT-5 antibody (Cell Signaling Technology, Danvers, MA),
a phospho-JAK2 antibody (BioSource, Camarillo, CA), a JAK2 antibody (Up-
state Biotechnology, Lake Placid, NY), a SOCS-2 antibody (Novus Biologicals,
Littleton, CO), a b-actin antibody (Sigma-Aldrich, St Louis, MO), total STAT5,
STAT5A, STAT5B, lamin B, and TBP antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA). Immunoblots were quantified by digital densitometry using
Scion Image software (Scion Corporation, Frederick, MD).
RT-qPCR Analyses
RNA was prepared and RT-qPCR performed as previously described (Inagaki
et al., 2007).
Recombinant Proteins
Recombinant human FGF21 (residues 33–209) with a hexahistidine-tag on the
amino terminus was expressed in E. coli and purified by sequential Ni-chelat-
ing and size-exclusion chromatography. Recombinant-mouse GH was ob-
tained from Dr. A.F. Parlow and the National Hormone and Peptide Program.
Statistical Analyses
Statistical analyses were performed using Minitab Release 14 Software (Mini-
tab, Inc., State College, PA). Comparisons of two groups were performed
using two-tailed Student’s t tests. Multiple groups were tested by one-way
ANOVA followed by Fisher’s least-significant-difference test for unpaired data
followed by Mann Whitney U test where appropriate. p < 0.05 was considered
significant.Cell Metabolism 8, 77–83, July 2008 ª2008 Elsevier Inc. 81
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